GuruFocus Premium Membership

Serving Intelligent Investors since 2004. Only 96 cents a day.

Free Trial

Free 7-day Trial
All Articles and Columns »

Weekly Guru Bargains Highlights: SD, CREE, AMLN, ICLR, CVD

guruyt

guruyt

4 followers
Last week’s top five guru bargain stocks were SANDRIDGE ENERGY INC, Cree Inc, Amylin Pharmaceuticals Inc, ICON plc, and Covance Inc. According to [url=GuruFocus updates, these stocks have declined the most since Gurus have bought.

SANDRIDGE ENERGY INC (SD): Down 25% Since T Boone Pickens Bought In the Quarter Ended on 2010-06-30

T Boone Pickens added to his holdings in Exploration & Production company SANDRIDGE ENERGY INC by 4.95% during the quarter ended 06/30/2010. He owned 1,888,954 shares of as of 06/30/2010. SandRidge Energy, Inc. is an oil and natural gas company headquartered in Oklahoma City with its principal focus on exploration and production. Sandridge Energy Inc has a market cap of $2 billion; its shares were traded at around $5.16 with a P/E ratio of 9.6 and P/S ratio of 3.3.

SD recently reported its third quarter results. Net income available to common stockholders of $297.7 million, or $0.73 per share fully diluted, for third quarter 2010 compared to net loss applicable to common stockholders of $104.1 million, or $0.58 per share fully diluted, in third quarter 2009.

Wallace Weitz bought 4,662,700 shares in the quarter that ended on 06/30/2010, which is 1.49% of the $1.82 billion portfolio of Weitz Wallace R & Co. T Boone Pickens owns 1,888,954 shares as of 06/30/2010, which accounts for 5.29% of the $208 million portfolio of BP Capital.

Prem Watsa owns 3,926,600 shares as of 06/30/2010, a decrease of 39.84% of from the previous quarter. This position accounts for 0.98% of the $2.35 billion portfolio of Fairfax Financial Holdings, Inc.. Arnold Schneider sold out his holdings in the quarter that ended on 06/30/2010.

Sell: Chairman, President & CEO Tom L. Ward sold 6,000,000 shares of SD stock on 10/06/2010 at the average price of 5.86. Tom L. Ward owns at least 21,863,075 shares after this. The price of the stock has decreased by 11.95% since.

Cree Inc. (CREE): Down 23% Since Steven Cohen Bought In the Quarter Ended on 2010-06-30

Steven Cohen added to his holdings in Semiconductors company Cree Inc. by 581.49% during the quarter ended 06/30/2010. He owned 53,967 shares of as of 06/30/2010. Cree, Inc. is a market-innovator and manufacturer of semiconductors that enhance the value of solid-state lighting, power and communications products by significantly increasing their energy performance and efficiency. Cree Inc. has a market cap of $5.75 billion; its shares were traded at around $54.49 with a P/E ratio of 29.9 and P/S ratio of 6.7. Cree Inc. had an annual average earning growth of 7.5% over the past 10 years.

Cree recently announced record revenue of $268.4 million for its first quarter of fiscal 2011, ended September 26, 2010. This represents a 59% increase compared to revenue of $169.1 million reported for the first fiscal quarter last year and a 1.5% increase compared to the fourth quarter of fiscal 2010. GAAP net income for the first quarter increased 176% year-over-year to $58.0 million, or $0.53 per diluted share, compared to GAAP net income of $21.0 million, or $0.23 per diluted share, for the first quarter of fiscal 2010.

PRIMECAP Management owns 8,522,807 shares as of 06/30/2010, which accounts for 0.93% of the $54.82 billion portfolio of PRIMECAP Management. Mario Gabelli sold out his holdings in the quarter that ended on 06/30/2010.

Sell: EXECUTIVE VICE PRESIDENT, COO Stephen Douglas Kelley sold 26,667 shares of CREE stock on 10/22/2010 at the average price of 49.58. Stephen Douglas Kelley owns at least 28,932 shares after this. The price of the stock has increased by 9.9% since. Other insiders have also decreased their positions in the company.

Amylin Pharmaceuticals Inc. (AMLN): Down 31% Since Jim Simons Bought In the Quarter Ended on 2010-06-30

Jim Simons added to his holdings in Biotechnology company Amylin Pharmaceuticals Inc. by 3301.53% during the quarter ended 06/30/2010. He owned 445,600 shares of as of 06/30/2010. Amylin Pharmaceuticals is a biopharmaceutical company committed to improving lives through the discovery, development and commercialization of innovative medicines. Amylin Pharmaceuticals Inc. has a market cap of $1.83 billion; its shares were traded at around $13.05 with and P/S ratio of 2.4.

AMLN recently reported its third quarter 2010 results. The Company reported total revenue of $156.1 million for the third quarter, including net product sales of $154.0 million. GAAP net loss for the quarter ended September 30, 2010 was $50.7 million, or $0.35 per share compared to $26.7 million, or $0.19 per share for the same period in 2009.

Edward Owens owns 1,557,200 shares as of 09/30/2010, which accounts for 0.18% of the $18.12 billion portfolio of Vanguard Health Care Fund. Carl Icahn owns 12,971,328 shares as of 06/30/2010, which accounts for 6.62% of the $0 million portfolio of Icahn Capital Management LP.

ICON plc (ICLR): Down 28% Since Steven Cohen Bought In the Quarter Ended on 2010-06-30

Steven Cohen added to his holdings in Biotechnology company ICON plc by 31.91% during the quarter ended 06/30/2010. He owned 7,395 shares of as of 06/30/2010. ICON plc is a global full service clinical research organization. Icon Plc has a market cap of $1.23 billion; its shares were traded at around $20.09 with a P/E ratio of 13.8 and P/S ratio of 0.9. Icon Plc had an annual average earning growth of 19.5% over the past 5 years.

George Soros owns 32,400 shares as of 06/30/2010, an increase of 15.3% from the previous quarter. This position accounts for 0.03% of the $3.31 billion portfolio of Soros Fund Management LLC. Jean-Marie Eveillard owns 8,000 shares as of 06/30/2010, a decrease of 42.86% of from the previous quarter. This position accounts for less than 0.01% of the $13.96 billion portfolio of First Eagle Investment Management, LLC.

Covance Inc. (CVD): Down 21% Since Jeremy Grantham Bought In the Quarter Ended on 2010-06-30

Jeremy Grantham added to his holdings in Biotechnology company Covance Inc. by 79.53% during the quarter ended 06/30/2010. He owned 399,320 shares of as of 06/30/2010. Covance Inc. is a contract research organization providing a wide range of product development services on a worldwide basis to the pharmaceutical, biotechnology and medical device industries. Covance Inc. has a market cap of $2.85 billion; its shares were traded at around $44.38 with a P/E ratio of 18.3 and P/S ratio of 1.4. Covance Inc. had an annual average earning growth of 13.4% over the past 10 years. GuruFocus rated Covance Inc. the business predictability rank of 3-star.

Covance recently reported earnings per diluted share for its second quarter ended June 30, 2010 of $0.49, including $0.09 of facility rationalization and other cost reduction actions during the second quarter, versus $0.60 in the first quarter of 2010 and $0.67 in the second quarter of 2009.

George Soros bought 7,200 shares in the quarter that ended on 06/30/2010, which is 0.01% of the $3.31 billion portfolio of Soros Fund Management LLC. Ron Baron owns 3,111,506 shares as of 06/30/2010, which accounts for 1.13% of the $14.08 billion portfolio of Baron Funds.

Buy: Chairman and CEO Joseph L Herring bought 20,000 shares of CVD stock on 08/02/2010 at the average price of 38.95. Joseph L Herring owns at least 237,202 shares after this. The price of the stock has increased by 13.94% since. There are mixed trades from other insiders.


Rating: 3.3/5 (3 votes)

Comments

Please leave your comment:


Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Email Hide